The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Methods to measure MRD & its role in predicting patient outcomes in AML
James Blachly, MD, The Ohio State University, Columbus, OH, discusses measurable residual disease (MRD) in acute myeloid leukemia (AML). The different technologies utilized to measure the presence of MRD in AML include flow cytometry, digital PCR, and next-generation sequencing (NGS). Dr Blachly highlights that MRD provides key insights into patient outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
MingSight Pharmaceuticals: Research Funding; AstraZeneca: Consultancy, Membership on an entity’s Board of Directors or advisory committees; INNATE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; KITE Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Astellas: Consultancy, Membership on an entity’s Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
